Payment overview · 2025
General Payments
$331.70
17 reported records · 7 companies
Healthcare provider profile · identity verified
David Woosuk Lee, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON, TX · NPI 1740402874
Verified facts
What the public records show
CMS Open Payments records show David Woosuk Lee, MD received $331.70 in general payments during 2025 across 17 reported records.
Novo Nordisk Inc accounted for 40.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $135.31 | 40.8% | 8 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $57.71 | 17.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.25 | 11.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.14 | 11.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.15 | 9.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.08 | 5.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.06 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $331.70 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $57.71 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.25 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 151 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
151 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
103 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 801 | 225 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 206 |
| Pravastatin Sodium | Pravastatin Sodium | 469 | 156 |
| Metformin Hcl | Metformin Hcl | 467 | 179 |
| Losartan Potassium | Losartan Potassium | 460 | 163 |
| Lisinopril | Lisinopril | 386 | 126 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 124 |
| Ezetimibe | Ezetimibe | 358 | 126 |
| Amlodipine Besylate | Amlodipine Besylate | 335 | 118 |
| Alendronate Sodium | Alendronate Sodium | 325 | 102 |
| Pantoprazole Sodium | Pantoprazole Sodium | 316 | 120 |
| Simvastatin | Simvastatin | 283 | 92 |
| Montelukast Sodium | Montelukast Sodium | 258 | 87 |
| Gabapentin | Gabapentin | 244 | 88 |
| Furosemide | Furosemide | 223 | 90 |
| Trazodone Hcl | Trazodone Hcl | 193 | 82 |
| Omeprazole | Omeprazole | 187 | 60 |
| Pioglitazone Hcl | Pioglitazone Hcl | 182 | 62 |
| Potassium Chloride | Potassium Chloride | 171 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 53 |
| Ozempic | Semaglutide | 151 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 54 |
| Tramadol Hcl | Tramadol Hcl | 142 | 38 |
| Methylprednisolone | Methylprednisolone | 134 | 102 |
| Allopurinol | Allopurinol | 133 | 45 |
| Glimepiride | Glimepiride | 131 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 48 |
| Spironolactone | Spironolactone | 121 | 44 |
| Carvedilol | Carvedilol | 120 | 44 |
| Jardiance | Empagliflozin | 117 | 45 |
| Eliquis | Apixaban | 103 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 43 |
| Trulicity | Dulaglutide | 96 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 87 | 27 |
| Synthroid | Levothyroxine Sodium | 86 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 80 | 66 |
| Meloxicam | Meloxicam | 80 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 27 |
| Temazepam | Temazepam | 79 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 24 |
| Fenofibrate | Fenofibrate | 68 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 24 |
| Azithromycin | Azithromycin | 57 | 44 |
| Alprazolam | Alprazolam | 55 | 28 |
| Celecoxib | Celecoxib | 53 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 18 |
| Clonidine Hcl | Clonidine Hcl | 49 | 28 |
| Sertraline Hcl | Sertraline Hcl | 49 | 19 |
| Ramipril | Ramipril | 44 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 20 |
| Atenolol | Atenolol | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 14 |
| Cholestyramine | Cholestyramine (With Sugar) | 40 | 18 |
| Linzess | Linaclotide | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 18 |
| Finasteride | Finasteride | 36 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 31 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 11 |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 12 |
| Valsartan | Valsartan | 33 | 11 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 12 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Baclofen | Baclofen | 28 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 26 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | 11 |
| Methimazole | Methimazole | 26 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | 14 |
| Famotidine | Famotidine | 24 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | 12 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | 11 |
| Nystatin | Nystatin | 22 | suppressed |
| Prolia | Denosumab | 22 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 14 |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | 11 |
| Estradiol | Estradiol | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Dutasteride | Dutasteride | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $331.70 · 17 records | Novo Nordisk Inc | AIRSUPRA, Kerendia, NURTEC ODT, OTEZLA, Ozempic, REPATHA, TRELEGY ELLIPTA, ZAVZPRET, t:slim X2 Insulin Pump with Control-IQ | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error